Abuse-resistant amphetamine compounds
DC CAFCFirst Claim
1. A method for treating a patient having attention deficit hyperactivity disorder, comprising orally administering to the patient in need thereof a pharmaceutically effective amount of L-lysine-d-amphetamine, or salts thereof.
5 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
222 Citations
15 Claims
- 1. A method for treating a patient having attention deficit hyperactivity disorder, comprising orally administering to the patient in need thereof a pharmaceutically effective amount of L-lysine-d-amphetamine, or salts thereof.
-
4. The method of 3, wherein the salt is a mesylate salt of L-lysine-d-amphetamine.
Specification